SOM Biotech is a clinical-stage bio-pharmaceutical company established at the Barcelona Science Park with the mission to discover and develop new indications of already known drugs (repurposing) using AI.


SOM Biotech has been using an artificial intelligence algorithm to identify candidates for drug repurposing more accurately, has 1 candidate (for Huntington’s disease) in phase 2b, and is looking to bring one new molecule to clinical phase 2 yearly.

It is using a unique and highly predictive algorithm to do so and has already signed a major licensing agreement. IPO planned for 2022 canceled due to market conditions. We participated in a bridge round to series B on very attractive terms